Lexicon Pharmaceuticals, Inc.  

(Public, NASDAQ:LXRX)   Watch this stock  
Find more results for LXRX
15.49
-0.26 (-1.65%)
After Hours: 15.49 0.00 (0.00%)
Dec 8, 4:39PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.15 - 15.75
52 week 7.65 - 19.62
Open 15.75
Vol / Avg. 652,094.00/643,259.00
Mkt cap 1.58B
P/E     -
Div/yield     -
EPS -0.30
Shares 104.04M
Beta 0.66
Inst. own 107%
Feb 27, 2017
Q4 2016 Lexicon Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 17, 2016
Lexicon Pharmaceuticals Inc at Jefferies Healthcare Conference
Nov 15, 2016
Lexicon Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 1, 2016
Q3 2016 Lexicon Pharmaceuticals Inc Earnings Call
Nov 1, 2016
Q3 2016 Lexicon Pharmaceuticals Inc Earnings Release
Sep 15, 2016
Lexicon Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -129.94% -3.60%
Operating margin -126.03% 1.13%
EBITD margin - 4.45%
Return on average assets -26.87% -0.83%
Return on average equity -71.78% -1.64%
Employees 120 -
CDP Score - -

Address

8800 Technology Forest Pl
THE WOODLANDS, TX 77381-1160
United States - Map
+1-281-8633000 (Phone)
+1-281-8638088 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.

Officers and directors

Raymond Debbane Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Lonnel Coats President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Jeffrey L. Wade J.D. Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
Age: 50
Bio & Compensation  - Reuters
Pablo Lapuerta M.D. Executive Vice President, chief medical officer
Age: 51
Bio & Compensation  - Reuters
Alan J. Main Ph.D. Executive Vice President - CMC and supply operations
Age: 61
Bio & Compensation  - Reuters
Praveen Tyle Ph.D. Executive Vice President of Research and Development
Age: 56
Bio & Compensation  - Reuters
James F. Tessmer Vice President - Finance & Accounting
Age: 55
Bio & Compensation  - Reuters
Gary Branch Vice President - Sales
Bio & Compensation  - Reuters
Kiernan Seth Ph.D. Vice President - Marketing
Bio & Compensation  - Reuters
Alexander Santini Chief Commercial Officer
Bio & Compensation  - Reuters